Physician profile
Christopher Saenz
NPI 1154361798
$383.21
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2020: $44.98 · 2021: $11.17 · 2022: $137 · 2024: $13.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $49.80 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.72 | 2022 | |
| Glaxosmithkline, LLC. | $37.49 | 2019-2020 | |
| Tris Pharma INC | $35.73 | 2019-2022 | |
| Pfizer INC. | $35.70 | 2022 | |
| Dermira, INC. | $28.13 | 2019 | |
| Vertiflex, INC. | $26.40 | 2019 | |
| Alk-Abello, INC | $24.75 | 2022 | |
| Sanofi Pasteur INC. | $23.32 | 2019 | |
| Genentech USA, INC. | $18.64 | 2019 | |
| Cranial Technologies, INC | $18.12 | 2022 | |
| Neos Therapeutics, Lp | $14.01 | 2020 | |
| Tempus Ai, INC | $13.46 | 2024 | |
| Dynavax Technologies Corporation | $12.94 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Saenz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.